Increase in expression of receptor activator of nuclear factor κB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis

Arthritis and Rheumatism

Volumn 46, Issue 11, 2002, Pages 3055-3064

  Lubberts, Erik ^a   Oppers Walgreen, Birgitte ^a   Pettit, Allison R ^b   Van Den Bersselaar, Liduine ^a   Joosten, Leo A B ^a   Goldring, Steven R ^b   Gravallese, Ellen M ^b   Van Den Berg, Wim B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CATHEPSIN K; COLLAGEN TYPE 2; FREUND ADJUVANT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE EROSION; CONTROLLED STUDY; GENE EXPRESSION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATION; MALE; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE AND BONES; CARRIER PROTEINS; COLLAGEN; DISEASE PROGRESSION; GLYCOPROTEINS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED DBA; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0036846152     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10607     Document Type: Article

References (33)

1. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
2. Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 2000;43:2143-51.
3. Quinn JM, Morfis M, Lam MH, Elliot J, Kartsogiannis V, Williams ED, et al. Calcitonin receptor antibodies in the identification of osteoclasts. Bone 1999;25:1-8.
4. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998;152:943-51.
5. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8.
6. Lacey DL, Timms E, Tan HL, Kelly MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
7. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells. J Biol Chem 1997;272:25190-4.
8. Anderson MA, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-9.
9. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki SI, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;95:3597-602.
10. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
11. Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186:2075-80.
12. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43:259-69.
13. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9.
14. Horwood NJ, Kartsogiannis V, Quinn JMW, Romas E, Martin TJ, Gillespie MT. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999;265:144-50.
15. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540-5.
16. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998;253:395-400.
17. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, de Smedt T, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-24.
18. Li J, Sarosi I, Yan X-Q, McCabe SM, Tan H-L, Capparelli C, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 2000;97:1566-71.
19. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
20. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-37.
21. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: An experimental model of arthritis. J Exp Med 1977;146:857-68.
22. Lubberts E, Joosten LAB, Chabaud M, van den Bersselaar L, Oppers B, Coenen-de Roo CJJ, et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000;105:1697-710.
23. Van den Berg WB, Joosten LAB, van de Putte LBA. Electrical charge of the antigen determines intraarticular handling and chronicity of arthritis in mice. J Clin Invest 1984;74:1850-9.
24. Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: A regulator of immune responses and bone physiology. Immunol Today 2000;21:495-502.
25. Hofbauer LC, Heufelder AE. The role of osteoprotegerin and receptor activator of nuclear factor κB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 2001;44:253-9.
26. Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JM, et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 1999;25:525-34.
27. Itonaga I, Fujikawa Y, Sabokbar A, Murray DW, Athanasou NA. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J Pathol 2000;192:97-104.
28. Glowacki J, Jasty M, Goldring S. Comparison of multinucleated cells elicited in rats by particulate bone, polyethylene, or polymethylmethacrylate. J Bone Miner Res 1986;1:327-31.
29. Goldring SR, Roelke M, Glowacki J. Multinucleated cells elicited in response to implants of devitalized bone particles possess receptors for calcitonin. J Bone Miner Res 1988;3:117-20.
30. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-99.
31. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 2001;408:600-5.
32. Thirunavukkarasu K, Miles RR, Halladay DL, Yang X, Galvin RJ, Chandrasekhar S, et al. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta): Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem 2001;276:36241-50.
33. Komuro H, Olee T, Kühn K, Quach J, Brinson DC, Shikhman A, et al. The osteoprotegerin/receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand system in cartilage. Arthritis Rheum 2001;44:2768-76.